Aptevo Therapeutics Inc. (APVO) Stock

Aptevo Therapeutics Inc. (APVO) is a Healthcare stock trading at $2.67 (as of 2026-08-21), with a market capitalization of $4.81M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing immunotherapeutic candidates for cancer, including its lead bispecific T-cell engager APVO436 in a Phase 1b trial for acute myelogenous leukemia and myelodysplastic syndrome. Its pipeline includes preclinical bispecific programs such as ALG.APV-527, APVO603, and APVO442.

Valuation — source: SEC EDGAR (first-party)
Price$2.67
Market Cap$4.81M
Price / Book0.80
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$3.11M
Net Margin257.8%
Return on Equity-437.1%
Current Ratio2.08
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($1.19M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMarvin L. White
Employees37
CountryUS
IPO Date2016-07-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Bolt Biotherapeutics, Inc. (BOLT)
  • Acurx Pharmaceuticals, Inc. (ACXP)
  • Dermata Therapeutics, Inc. (DRMA)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • Pulmatrix, Inc. (PULM)
  • Lakewood-Amedex Biotherapeutics Inc. (LABT)
  • Revelation Biosciences, Inc. (REVB)
APVO earnings history · APVO institutional & insider holders · APVO KPIs & operating metrics · APVO financials · APVO investor presentations & press releases · APVO SEC filings · APVO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.